Health technology assessment
Sector Deep DivesThe national process deciding whether a health system funds a new treatment, and at what price.
Also written: HTA, health technology appraisal
Approval answers whether a treatment works and is safe. Health technology assessment answers whether the system will pay for it, comparing added clinical benefit against the current standard of care and, in several systems, weighing that benefit against cost. NICE performs it in England, the G BA advised by IQWiG in Germany, the HAS in France and AIFA in Italy.
The methods differ and so do the conclusions, which is the part that matters commercially. The same dossier can be judged to offer substantial added benefit in one country and none in another, so one European authorisation produces as many commercial outcomes as there are markets.
This is the sharpest structural difference between European and American healthcare economics. In the United States a manufacturer sets a list price and negotiates rebates privately with insurers and pharmacy benefit managers. In most of Europe a public body decides, and the price is an output of that decision rather than an input.
A European regulation now provides for a joint clinical assessment at European level, phased in by product type. It converges the evidence review. It does not converge the money, because pricing and reimbursement remain national competences.
Worked example
A medicine is authorised across the EU on the same day everywhere.
It is funded quickly in one market at close to the price asked, funded in another only after a confidential discount, and left unfunded in a third where the assessment found no added benefit over an existing generic.
Peak European sales are therefore a sum of national outcomes. Treating them as a single assumption is the most common way a European pharma forecast goes wrong.